Enabling surgeons to use a person’s own tissue instead of synthetic implants and fillers to improve procedures like breast and facial reconstruction.

Moving beyond traditional PEGylation in drug delivery and pioneering the next generation of immune-stealth biologics.

Low-cost, high-throughput, scalable purification of Fc fusion proteins, AAVs, nucleic acids, and enzymes. Acquired by Donaldson Company in February 2023.

Using non-fouling polymer brushes for improved detection of protein analytes in immunoassays. Acquired by Immucor in October 2014.

Developing ELP fusion therapies to improve stability, bioavailability, activity, and ease of administration of protein and peptide drugs. Went public in 2018.

Developing cost-effective and simple test cartridges that enable drug monitoring, chronic disease management, acute disease screening, and more with a single drop of blood.